⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15506875 | 0.90 | NPSR1 (0.34) | — | |
| SCHEMBL15506868 | 0.90 | NPSR1 (0.39) | — | |
| SCHEMBL10527013 | 0.88 | NPSR1 (0.38) | — | |
| SCHEMBL19641035 | 0.84 | KDM4E (0.38) | — | |
| SCHEMBL26741050 | 0.82 | TSHR (0.33) | — | |
| Methyl Carbamate SCHEMBL11664166 | 0.81 | ALDH1A1 (0.37) | — | |
| Carbamic Acid SCHEMBL28572811 | 0.81 | ALDH1A1 (0.37) | — | |
| SCHEMBL24858087 | 0.80 | — | — | |
| SCHEMBL10481775 | 0.78 | TSHR (0.34) | — | |
| SCHEMBL3076558 | 0.78 | TSHR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119451683-A | Oligonucleotide compositions and methods thereof | 艾米利克斯制药公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-110105434-B | Stapled and stitched polypeptides and uses thereof | 哈佛大学的校长及成员们 | 2024-09-17 | — | — | CN | disclosed |
| CN-118059096-A | Methods of treating CNS disorders | 杭州高光制药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-116490180-B | Methods of treating CNS disorders | 杭州高光制药有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2022135442-A1 | CDK2 INHIBITOR AND PREPARATION METHOD THEREFOR | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114585370-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114502177-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-113748116-A | Techniques useful for oligonucleotide preparation | 波涛生命科学有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-105307667-B | Stapled and sutured polypeptides and uses thereof | 哈佛大学的校长及成员们 | 2019-04-19 | — | — | CN | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| WO-2013163466-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| CN-102365025-A | Conjugate-based systems for controlled drug delivery | SMARTCELLS INC | 2012-02-29 | — | — | CN | disclosed |
| WO-2011091532-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |